Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Transmission-based Precautions I: Contact, Enteric, and Droplets01:17

Transmission-based Precautions I: Contact, Enteric, and Droplets

Transmission-based precautions are for patients known to be infected or suspected to be infected or colonized with organisms that pose a significant risk to others. Some transmission-based precautions include contact, enteric, and droplet.
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals.

Gastroenterologia y hepatologia·2021
Same author

Dynamics of creatinine estimated glomerular filtration rate using one or more antiretrovirals that inhibit creatinine tubular secretion.

The Journal of antimicrobial chemotherapy·2021
Same author

Higher relapse rate among HIV/HCV-coinfected patients receiving sofosbuvir/ledipasvir for 8 vs 12 weeks.

The Journal of infection·2019
Same author

[Prevalence of undiagnosed human immunodeficiency virus infection in an emergency department and the characteristics of newly diagnosed patients].

Emergencias : revista de la Sociedad Espanola de Medicina de Emergencias·2017
Same author

[Pharmacokinetic interactions].

Enfermedades infecciosas y microbiologia clinica·2013
Same author

Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2009
Same journal

New COVID-19 vaccination recommendations in Spain: Optimizing for next seasons.

Enfermedades infecciosas y microbiologia clinica·2025
Same journal

[Description of 12 HIV-positive patients who have had the COVID-19 in our area].

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

[SARS-CoV-2 infection as trigger multisystem inflammatory syndrome?]

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

Impact of COVID-19 on Madrid hospital system.

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

[COVID-19 and influenza A coinfection: a matter of principle].

Enfermedades infecciosas y microbiologia clinica·2024
Same journal

COVID and CARE®. Mobile application for monitoring SARS-CoV-2 positive patients after hospitalization.

Enfermedades infecciosas y microbiologia clinica·2024
See all related articles

Related Experiment Video

Updated: Jun 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

[Etravirine in special populations].

Ignacio de los Santos Gil1

  • 1Hospital Universitario de la Princesa, Madrid, España. isantosg@hotmail.com

Enfermedades Infecciosas Y Microbiologia Clinica
|February 2, 2010
PubMed
Summary
This summary is machine-generated.

Etravirine, a new non-nucleoside reverse transcriptase inhibitor, offers a safer antiretroviral treatment option for HIV patients with comorbidities like hepatitis or psychiatric disorders. Its favorable side effect profile and lower teratogenicity risk benefit diverse patient groups.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Related Experiment Videos

Last Updated: Jun 16, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage (Tropism) by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Hepatology

Background:

  • Antiretroviral therapy selection for HIV patients with comorbidities demands comprehensive understanding of drug interactions, pharmacokinetics, and adverse effects.
  • Many antiretroviral drugs pose risks in specific conditions, highlighting the need for safer treatment alternatives.
  • Etravirine represents a novel non-nucleoside reverse transcriptase inhibitor with potential advantages in managing complex patient cases.

Purpose of the Study:

  • To evaluate the suitability and safety of etravirine in HIV-infected patients with specific comorbidities.
  • To assess the potential benefits of etravirine regarding reduced adverse effects and improved treatment adherence.
  • To explore the application of etravirine in special populations, including those with viral hepatitis, psychiatric disorders, and women of reproductive age.

Main Methods:

  • Literature review and analysis of pharmacokinetic and pharmacodynamic data for etravirine.
  • Examination of clinical trial data and case reports concerning etravirine use in patients with comorbidities.
  • Assessment of safety profiles, including adverse events and teratogenicity, associated with etravirine.

Main Results:

  • Etravirine demonstrates a lower risk of secondary effects compared to other non-nucleoside reverse transcriptase inhibitors.
  • Its use is indicated for patients coinfected with hepatitis B/C virus and those with psychiatric conditions or on psychotropic medications.
  • Etravirine shows a reduced risk of teratogenicity, making it a potentially safer option for women of childbearing potential.

Conclusions:

  • Etravirine offers a promising antiretroviral treatment option for HIV patients with various comorbidities.
  • Its favorable safety profile supports its use in complex patient populations, potentially improving treatment outcomes and adherence.
  • Further research is warranted for specific populations like those with renal insufficiency and pediatric patients, though initial data are emerging.